Investors & Media

Investors & Media

Corporate Profile

Aileron Therapeutics is focused on transforming the experience of chemotherapy for cancer patients, enabling them to fight cancer without the fear or burden of chemotherapy-induced side effects. We are advancing ALRN-6924, our first-in-class dual MDM2/MDMX inhibitor currently in clinical development, to provide a single medicine to protect multiple healthy cell types throughout the body from chemotherapy while ensuring chemotherapy continues to destroy cancer cells.

More >>


Data Provided by Refinitiv. Minimum 15 minutes delayed.

Investor Contacts

Alexander Lobo

Stern Investor Relations